REPLIGEN CORP Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
REPLIGEN CORP (RGEN) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $58.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-14.
Financial Statements › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2025-03-14
- REPLIGEN CORP unrecognized tax benefits, income tax penalties and interest expense for fiscal 2024 was $58.00M, a 286.67% increase from fiscal 2023.
- REPLIGEN CORP unrecognized tax benefits, income tax penalties and interest expense for fiscal 2023 was $15.00M, a 37.50% decline from fiscal 2022.
- REPLIGEN CORP unrecognized tax benefits, income tax penalties and interest expense for fiscal 2022 was $24.00M.
- REPLIGEN CORP unrecognized tax benefits, income tax penalties and interest expense for fiscal 2021 was -$29.00M, a 270.59% decline from fiscal 2020.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month as first filed |
|---|---|---|
| 2024-12-31 | $58.00M 10-K · filed 2025-03-14 | |
| 2023-12-31 | $15.00M 10-K · filed 2025-03-14 | |
| 2022-12-31 | $24.00M 10-K/A · filed 2024-11-18 | |
| 2021-12-31 | -$29.00M 10-K · filed 2023-02-22 | $29.00M 10-K · filed 2022-02-17 |
| 2020-12-31 | $17.00M 10-K · filed 2023-02-22 | |
| 2019-12-31 | $5.00M 10-K · filed 2022-02-17 | |
| 2018-12-31 | $1.00M 10-K · filed 2021-02-24 | |
| 2017-12-31 | $1.00M 10-K · filed 2020-02-26 | |
| 2016-12-31 | $16.00K 10-K · filed 2017-02-23 | |
| 2015-12-31 | $272.00K 10-K · filed 2016-02-25 | |
| 2014-12-31 | $139.00K 10-K · filed 2015-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |